Abstract: A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.

Abstract: A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.

Abstract: The invention relates to a dosing regimen for administering a liquid pharmaceutical composition of amantadine hydrochloride to a patient having a traumatic brain injury. The dosing regimen includes administering a first dose and administering a second dose of amantadine hydrochloride. The step of administering a first dose is by an intravenous route and the first dose comprises between 100 mg and 200 mg of amantadine hydrochloride in an aqueous solution of about 200 ml to about 300 ml over a period of about two to about four hours. The step of administering a second dose is by an intravenous route and the first dose comprises between 100 mg and 200 mg of amantadine hydrochloride in an aqueous solution of about 200 ml to about 300 ml over a period of about two to about four hours. The second dose is administered after at least about four to at least about six hours after the completion of administration of the first dose.

Abstract: Compositions comprising cannabidiol and one or more compounds which are inhibitors of CYP2C19 and CYP3A4 enzymes are disclosed. Methods of treating pain, epilepsy, sleep deprivation, vomiting, nausea, psychosis, anxiety, depression, movement disorders, and other neuropsychiatric or neurogenic diseases using such compositions are also provided. Compositions comprising cobicistat, or pharmaceutically acceptable isomers, salts, and/or solvates thereof; and at least one therapeutic agent which is metabolized by CYP2C19, and optionally CYP3A4, are provided. Methods for inhibiting CYP2C19, and optionally CYP3A4, in a patient in need thereof are also provided, comprising administering to the patient an amount of cobicistat, or pharmaceutically acceptable isomers, salts, and/or solvates thereof, effective for inhibiting CYP2C19, and optionally CYP3A4, in the patient.

Abstract: Provided herein are compositions, delivery devices, and methods relating to the delivery of tetrabenazine and/or deuterated tetrabenazine, for example, continuous or substantially continuous delivery such as transdermal delivery, for the treatment of a hyperkinetic movement disorder. Also provided are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, pharmaceutical compositions comprising tetrabenazine and/or a deuterated tetrabenazine, methods of preparing the same, and methods of using the same for example, for the treatment of a hyperkinetic movement disorder.

Abstract: A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.

Abstract: A transdermal delivery system comprising a drug-containing matrix layer, a release liner and a backing layer. The drug-containing matrix layer further comprises a methylphenidate base, an adhesive polymer made up of a styrene rubber block copolymer having a styrene content of 24% or above by weight of the adhesive polymer; the adhesive polymer is present in an amount of 20% to 45% by weight of the drug-containing matrix layer, a tackifier present in an amount of 30% to 45% by weight of the drug-containing matrix layer, and a hydrocarbon plasticizer present in an amount of 1% to 30% by weight of the drug-containing matrix layer.